close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Statins and Beta-Blockers May Ease Heart Disease Symptoms

While statins and beta-blockers may not prevent primary heart disease in higher-risk people, they may reduce initially symptoms, according to a study published in the Annals of Internal Medicine and reported by MedPage Today on February 21, 2006.

Investigators Alan S Go, MD, of Kaiser Permanente of Northern California here, and colleagues, found that using statins and beta-blockers to prevent coronary artery disease may mean that initial symptoms may present as angina, instead of a heart attack.

Clinical Trial

The researchers conducted a retrospective case-control study of data from 1,384 people enrolled in Kaiser Permanente of Northern California. Participants showed the first signs of coronary disease in 2001- 2003. A total of 438 had stable exertional angina and 916 had an acute heart attack.

When the investigators compared data from these two groups, they found that the people who had angina were much more likely to have been taking statins, compared with the people who had a heart attack (40% versus 19%), respectively.

Data regarding beta-blockers use followed the same pattern: 48% of the people who experienced were taking beta-blockers, versus only 19% of people who had had heart attacks.

All patients taking these drugs were taking them for primary prevention and not because of any previous coronary artery disease symptoms. (Statins had been prescribed for dyslipidemia, while beta-blockers had been prescribed for hypertension.)

Data analysis showed that the people who had had a heart attack were more likely to be male, physically inactive, smokers and hypertensive. After adjusting for these variables, statin use was associated with a 55% lower risk of heart attack as a first symptom, and beta-blockers were associated with 74% lower risk.

Go et al also analyzed the use of alpha-blockers, ACE inhibitors, angiotensin II receptor blockers and (among women) hormone therapy. However, use of none of these drugs correlated with reduced risk of heart attack.

"Although our findings must be confirmed by randomized studies, they suggest that use of statins and beta-blockers for primary prevention may not only reduce the incidence of coronary artery disease but may also increase the likelihood of more stable, lower-risk clinical presentation of coronary atherosclerosis," the authors wrote.

Interpreting Results

In an accompanying editorial published in the same issue, Sidney C Smith Jr, MD, of the University of North Carolina at Chapel Hill wrote, "This finding may be important, and the authors are appropriately cautious" about interpretation, according to MedPage Today.

"Go and colleagues acknowledge that because their study was not prospective, it lacked information on confounding factors such as the use of aspirin therapy to prevent coronary heart disease," Dr Smith reportedly added.

"If aspirin therapy was strongly associated with the use of statins and beta-blockers, it could explain some of the effect of these two drugs." However, if borne out by randomized trials, "these findings could have a substantial effect on patient care."

Sources:> Drugs to Prevent Heart Disease May Soften its First Symptoms, MedPage Today, February 21, 2006. Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Alan S Go, et al. Annals of Internal Medicine, volume 144(4), pages 229-238, February 21, 2006. Can preventive therapy alter the initial presentation of coronary heart disease? Smith SC, Annals of Internal Medicine, volume 144, pages 296-297, February 21, 2006.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...